Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPX-101 safety study in cystic fibrosis
NCT03056989Phase 1Completed
- Sponsor
- Spyryx Biosciences
- Start
- May 2017
- Primary completion
- Aug 2017
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of SPX-101 in cystic fibrosis (CF) (3 arms), sponsored by Spyryx Biosciences. Primary endpoint: Number of participants with adverse events. Started May 2017; status: completed.
02
Drugs
SPX-101
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT03056989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03056989.